SLS International (AMEX:SLS) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of SLS International (AMEX:SLS) from a sell rating to a hold rating in a research note published on Wednesday morning, reports.

According to Zacks, “SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company’s product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States. “

A number of other research analysts also recently issued reports on SLS. Maxim Group downgraded SLS International from a buy rating to a hold rating in a report on Friday, March 22nd. Alliance Global Partners started coverage on SLS International in a research note on Monday, April 8th. They set a buy rating and a $4.50 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $5.55.

SLS International Company Profile

SLS international is a language services company which offers translations globally. The Company offers a range of services, including multilingual translations into all Spanish variants, localization, adaptation and content editing. It uses the mother-tongue linguists in order to meet the demanding standards.

Featured Story: Hedge Funds

Get a free copy of the Zacks research report on SLS International (SLS)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for SLS International (AMEX:SLS)

Receive News & Ratings for SLS International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SLS International and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit